Cardinal Health Inc. closed 5.54% short of its 52-week high of $139.50, which the company achieved on April 3rd.

This was the stock's third consecutive day of losses.

BofA raised the firm’s price target on Cardinal Health (CAH) to $155 from $150 and keeps a Buy rating on the shares. The recent introduction of ...

Following recent U.S. Food and Drug Administration (FDA) approval 2, and in preparation for commercial launch in H1 2025, Telix has contracted with Cardinal Health to enable availability across a wide ...

In a report released today, Allen Lutz from Bank of America Securities maintained a Buy rating on Cardinal Health (CAH – Research Report). The ...

The stock's rise snapped a four-day losing streak.

According to WittKieffer’s 2025 report “Healthcare CEO Reimagined,” the traditional CEO archetype is being redefined ...

Cardinal Health (CAH) closed the latest trading day at $128.88, indicating a -1.2% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 3.46%.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

Telix Pharmaceuticals TLX recently announced a major step in expanding access to its next-generation prostate cancer imaging agent, Gozellix, by selecting Cardinal Health CAH as a key U.S. commercial ...

March 26, 2025 • As the U.S. health system grapples with new outbreaks and the risk of old diseases making a comeback, we're looking to the past to inform how people in marginalized communities ...